CMF Wins Full Dismissal of FINRA Customer Case Against Broker and Broker-Dealer and Broker Wins Expungement from CRD

Press Release – New York, NY – July 8, 2020 – Securities and corporate law firm Carmel, Milazzo & Feil LLP announced today that it obtained a FINRA arbitration award (Case No. 19-02754) dismissing all claims asserted by a former customer against brokerage firm First Standard Financial Company (“FSF”) and broker Michael Christopher Blumer. The award also recommended expungement of any and all references to the arbitration claim from Mr. Blumer’s CRD records as maintained by FINRA.  

The customer asserted claims for unsuitability, unauthorized trading, breach of fiduciary duty, breach of the duty of good faith and fair dealing, breach of contract; misrepresentation and omission; fraud; negligence; and failure to supervise, all of which were aggressively defended .  

After a full presentation of evidence by CMF attorneys at the hearing of this matter, the arbitrator found that “Claimant misrepresented the length of his relationship with Blumer; his significant level of experience as a sophisticated investor; and his unequivocal, repeated interest and decisions to invest in speculative, maximum growth investments as well as trading in options, which were consistent with his chosen tolerance for high risk. The Arbitrator also found that Claimant’s claim and allegations were not supported with any credible evidence, thus Claimant filed a false claim.”

CMF is pleased with this result for its clients and maintain that this award is an affirmation that all customer arbitrations should be carefully vetted and that a broker and brokerage firm have avenues and recourse available to defend themselves and seek exoneration .  CMF attorneys are available to discuss how we can assist in the defense of your next customer or industry case.  We can be contacted at contact@cmfllp.com or (212) 658-0458.

About Carmel, Milazzo & Feil LLP
Carmel, Milazzo & Feil LLP is a nationally recognized securities and corporate law firm that provides experienced representation in all matters involving the securities industry. Our attorneys specialize in advising clients on private placements, initial (IPOs) and secondary public offerings, alternative public offerings, preparation of SEC filings and listings on the NYSE, NASDAQ and OTC Markets. In addition, our litigation and arbitration attorneys are highly skilled in representing clients from routine lawsuits to complex cases before the SEC, FINRA, and other tribunals, as well as State and Federal Courts.

The information on this site is for general informational purposes only.  The information presented in this site is not legal advice or a legal opinion, and it may not necessarily reflect the most current legal developments.  You should seek the advice of legal counsel of your choice before acting upon any of the information in this site. These materials may be considered advertising for legal services under the laws and rules of professional conduct of the jurisdictions in which we practice.  Under New York’s Code of Professional Responsibility, portions of this website constitute attorney advertising. This website is a communication providing public information about our firm’s availability for professional employment.

CMF Wins FINRA Expungement of Customer Complaint for Registered Representative

Press Release – New York, NY – June 24, 2020 – Securities and corporate law firm Carmel, Milazzo & Feil LLP announced today that it obtained a FINRA arbitration award (Case No. 19-00448) recommending expungement relief to a broker client of any and all references to a customer arbitration and despite the climate of denial of such applications and issues marshalling evidence relative to a now defunct broker dealer.  

The broker maintained that he was named to the underlying arbitration in error and CMF attorneys provided ample evidentiary support for that position.  As a result of all such proofs submitted, the arbitrator made an affirmative finding that the underlying arbitration claim was “factually impossible or clearly erroneous and the client was not involved in the alleged investment-related sales practice violation.” 

CMF is pleased with the result for our deserving client and maintain that this finding is an affirmation that a broker’s CRD need not be forever marred with an unfounded complaint or arbitration that appears on his or her license.  CMF attorneys are available to discuss how we can assist with your next expungement issue.  We can be contacted at contact@cmfllp.com or (212) 658-0458.

About Carmel, Milazzo & Feil LLP
Carmel, Milazzo & Feil LLP is a nationally recognized securities and corporate law firm that provides experienced representation in all matters involving the securities industry. Our attorneys specialize in advising clients on private placements, initial (IPOs) and secondary public offerings, alternative public offerings, preparation of SEC filings and listings on the NYSE, NASDAQ and OTC Markets. In addition, our litigation and arbitration attorneys are highly skilled in representing clients from routine lawsuits to complex cases before the SEC, FINRA, and other tribunals, as well as State and Federal Courts.

The information on this site is for general informational purposes only.  The information presented in this site is not legal advice or a legal opinion, and it may not necessarily reflect the most current legal developments.  You should seek the advice of legal counsel of your choice before acting upon any of the information in this site. These materials may be considered advertising for legal services under the laws and rules of professional conduct of the jurisdictions in which we practice.  Under New York’s Code of Professional Responsibility, portions of this website constitute attorney advertising. This website is a communication providing public information about our firm’s availability for professional employment.

PARTNER ROSS DAVID CARMEL AGAIN NAMED “SUPER LAWYER RISING STAR” BY THOMSON REUTERS

Press Release – New York, NY – April 15, 2020 – Securities and Corporate law firm Carmel, Milazzo & Feil LLP (“CMF”) is proud to announce that for the fourth consecutive year, partner Ross David Carmel has been named a “Super Lawyer Rising Star” by Thomson Reuters a distinction reserved for only 2.5% of all attorneys in the New York Metro area.  The announcement will appear in the New York Times. 

Carmel, Milazzo & Feil Obtain Successful Appeal and Vacatur of FINRA Disciplinary Finding

Press Release – New York, NY – April 13, 2020 – Securities and corporate law firm Carmel, Milazzo & Feil LLP announced today that attorneys Timothy Feil, Esq., and Craig Riha, Esq., obtained an appellate decision from the National Adjudicatory Council (“NAC”), the Financial Industry Regulatory Authority (“FINRA”) committee that reviews FINRA disciplinary proceedings, for their client Southeast Investments, N.C., Inc. (“SEI”). The NAC vacated disciplinary findings made by the FINRA Office of Hearing Officers (“OHO”).

Mr. Feil and Mr. Riha did not represent SEI during the original OHO disciplinary proceeding.  The OHO found that SEI had willfully violated securities laws and FINRA Rules by failing to inspect certain of its branch offices and by failing to maintain various e-mail correspondence. As a result, SEI was levied with significant fines and a statutory disqualification pursuant to the finding of willfulness.  Based upon the NAC’s Decision, the finding of failure to inspect branch offices was vacated, and the finding of failure to maintain e-mails was significantly reduced. In addition, all OHO findings made against SEI of willfulness were vacated, resulting in a vacatur of the statutory disqualification against it. Finally, the NAC significantly reduced fines imposed against SEI by nearly $100,000 given the vacatur of the OHO findings as against SEI. 

Mr. Feil and Mr. Riha are pleased with the NAC result for SEI and maintain that this NAC Decision is affirmation that broker dealers should not accept their fate as determined by FINRA Department of Enforcement or OHO when the objective facts tell a different story, especially where such determinations can drastically affect the business operations and legacy of the firm and its representatives.

See Dept. of Enforcement v. Southeast Investments N.C., Inc., Complaint No. 2014039285401.

You can find the decision here: https://www.finra.org/sites/default/files/fda_documents/2014039285401%20Southeast%20Investments%20CRD%2043035%20Frank%20Harmon%20Black%20CRD%2022451%20NAC%20Decision%20jm%20%282019-1563542383902%29.pdf

About Carmel, Milazzo & Feil LLP
Carmel, Milazzo & Feil LLP is a nationally recognized securities and corporate law firm that provides experienced representation in all matters involving the securities industry. Our attorneys specialize in advising clients on private placements, initial (IPOs) and secondary public offerings, alternative public offerings, preparation of SEC filings and listings on the NYSE, NASDAQ and OTC Markets. In addition, our litigation and arbitration attorneys are highly skilled in representing clients from routine lawsuits to complex cases before the SEC, FINRA, and other tribunals, as well as State and Federal Courts.

The information on this site is for general informational purposes only.  The information presented in this site is not legal advice or a legal opinion, and it may not necessarily reflect the most current legal developments.  You should seek the advice of legal counsel of your choice before acting upon any of the information in this site. These materials may be considered advertising for legal services under the laws and rules of professional conduct of the jurisdictions in which we practice.  Under New York’s Code of Professional Responsibility, portions of this website constitute attorney advertising. This website is a communication providing public information about our firm’s availability for professional employment.

Carmel, Milazzo & Feil LLP Represents Co-Diagnostics In $4.2 Million Registered Direct Offering

Press Release – New York, NY – February 27, 2020 –  Securities and corporate law firm Carmel, Milazzo & Feil LLP announced today that it has represented Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, in a registered direct offering priced at-the-market under Nasdaq rules of 470,000 shares of its common stock, at a purchase price of $9.00 per share, in a registered direct offering priced at-the-marked under the Nasdaq rules. The closing of the offering is expected to occur on or about March 2, 2020, subject to the satisfaction of customary closing conditions. The gross proceeds to the Company, before deducting placement agent fees and other offering expenses, are expected to be approximately $4.2 million. Co-Diagnostics intends to use the net proceeds from this offering for acquisition of PCR (polymerase chain reaction) equipment and raw materials to be used in connection with sale of tests used to diagnose infectious disease, including strains and mutations of coronavirus, as well as research and development costs associated with test development for additional pathogens and test menu expansion, and for working capital and other general corporate purposes.

H.C. Wainwright & Co. is acting as the exclusive lead placement agent for the offering. Maxim Group LLC is acting as co-placement agent.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in certain verticals or markets, (iv) capital resources and runway needed to advance the Company’s products and markets, (v) increased sales in the near-term, (vi) flexibility in managing the Company’s balance sheet, (vii) anticipation of business expansion, (viii) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages and (ix) statements regarding the offering, the expected gross proceeds from the offering, the intended use of proceeds and the timing of the closing of the offering. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances, including market conditions. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Carmel, Milazzo & Feil LLP Represents Co-Diagnostics In $10.2 Million Registered Direct Offering

Press Release – New York, NY – February 11, 2020 –  Securities and corporate law firm Carmel, Milazzo & Feil LLP announced today that it has represented Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, in a registered direct offering priced at-the-market under Nasdaq rules of 3,324,676 shares of its common stock, at a purchase price per share of $3.08, in a registered direct offering priced at-the-marked under the Nasdaq rules. The gross proceeds to the Company, before deducting placement agent fees and other offering expenses, are expected to be approximately $10.2 million. Co-Diagnostics intends to use the net proceeds from this offering for acquisition of PCR (polymerase chain reaction) equipment to be used in connection with sales of reagents used for tests to diagnose infectious disease, including strains and mutations of coronavirus, as well as research and development costs associated with test development for additional pathogens and test menu expansion, and for working capital and other general corporate purposes.

H.C. Wainwright & Co. is acting as the exclusive lead placement agent for the offering.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in certain verticals or markets, (iv) capital resources and runway needed to advance the Company’s products and markets, (v) increased sales in the near-term, (vi) flexibility in managing the Company’s balance sheet, (vii) anticipation of business expansion, (viii) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages and (ix) statements regarding the intended use of proceeds of the offering. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances, including market conditions. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Carmel, Milazzo & Feil LLP Represents Co-Diagnostics In $5 Million Registered Direct Offering

Press Release – New York, NY – January 28, 2020 –  Securities and corporate law firm Carmel, Milazzo & Feil LLP announced today that it has represented Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, in a registered direct offering priced at-the-market under Nasdaq rules of 3,448,278 shares of common stock for a purchase price of $1.45 per share, for gross proceeds of approximately $5.0 million.

H.C. Wainwright & Co. acted as the exclusive lead placement agent for the offering. Maxim Group LLC acted as co-placement agent.

Co-Diagnostics intends to use the net proceeds from this offering for further commercialization and expansion of its infectious disease testing, agrigenomics, and vector control verticals, acceleration of sales and technology licensing activities, ongoing development of additional applications for its technology in markets related to liquid biopsy and next-gen sequencing, and for working capital and other general corporate purposes.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in certain verticals or markets, (iv) capital resources and runway needed to advance the Company’s products and markets, (v) increased sales in the near-term, (vi) flexibility in managing the Company’s balance sheet, (vii) anticipation of business expansion, (viii) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages and (ix) statements regarding the intended use of proceeds of the offering. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances, including market conditions. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Carmel, Milazzo & Feil LLP Represents YayYo Inc. (NASDAQ: YAYO) in $10.5 Million Initial Public Offering (IPO)

Press Release – New York, NY – November 18, 2019 –  Securities and corporate law firm Carmel, Milazzo & Feil LLP announced today that it has represented YayYo Inc. (NASDAQ: YAYO), a leading provider of vehicles to the rideshare industry, through its wholly-owned subsidiary, Rideshare Car Rentals, LLC, bridging the gap between rideshare drivers needing a quality vehicle and rideshare companies that depend on attracting and keeping drivers with quality vehicles, in a $10.5 Million Initial Public Offering on the NASDAQ.

YayYo Inc. sold 2,625,000 shares of its common stock at a public offering price of $4.00 per share for gross proceeds of $10.5 million, before deducting offering expenses.

Aegis Capital Corp. and WestPark Capital, Inc. are acting as joint book running managers.

Implications of United States Broker-Dealer Regulations on Securities Tokens Transactions

Introduction

Security token transactions have become rather common in day-to-day operations with regard to both initial private and public offerings and secondary markets. As a result of the active position of the United States Securities and Exchange Commission (the “SEC”) in setting the regulatory framework for securities offerings by means of distributed ledger technology, blockchain investors and issuers are well-educated (sometimes, in a hard way) about their eminent compliance obligations to either register security tokens or ensure that the relevant transaction falls under an exemption from registration.

Nevertheless, a significant number of market participants whether they are individuals or legal entities remain ambivalent to a less obvious but not less important consequence of trading securities in their tokenized form: namely, the extensive broker-dealer regulations that may be applicable to the activities of said market participants.

It seems that there are two main reasons for such a peripheral status of the matter. First, the topic of broker-dealer regulations in the context of trading security tokens remains novel to some extent, partially, because the SEC has not commenced any newsworthy proceedings to date relating to broker-dealer regulations in the token trade realm. Therefore, the lack of awareness is anticipated. Secondly, the unique nature of the blockchain transactions may actually discourage market participants from registration due to fear of not being able to comply with their reporting obligations and with the best practices standard. Interestingly, the SEC admitted that “the ability of a broker-dealer to comply with aspects of [… the relevant regulations] may not be available or effective in the case of certain digital assets” (Joint Staff Statement on Broker-Dealer Custody of Digital Asset Securities). Audacious registered brokers who are willing to commit to the industry are not in abundance.

On the one hand, broker-dealer activity is inevitable in any developed securities market. Thus, numerous individuals and legal entities fulfill the needs of the global communities (with or without second thoughts whether such activity would subject them to the SEC’s jurisdiction). Simply put, in the situation of demand, the supply will commensurate regardless of the license status. On the other hand, the broker-dealer compliance cases may very well become the second “wave” of federal enforcement actions brought by the SEC. Based on the aforesaid, it’s worth choosing an awareness of potential law enforcement risks over prevarication of pointed questions, if and when asked. Consequently, this article is intended to describe some of the aspects of the broker-dealer regulations and the possible implications of the said regulation on the securities tokens market.

Types of Tokens

The instant article addresses solely security tokens. For the purpose of clarification, a token can be deemed a security whether it was intentionally designed to fit within the rubric of securities laws or regarded as such by a regulator based on the Howey test (four-pronged SEC v. W.J. Howey, 328 U.S. 293 (1946) under which an instrument is a security if it relates to (i) an investment of money (ii) in a common enterprise (iii) with a reasonable expectation of profits (iv) to be derived from the entrepreneurial and managerial efforts of others).[1] Standalone cryptocurrency trading or trading of utility tokens may also have consequences related to broker-dealer regulations, but they will not be discussed here.

The International Token Market

Whether it fits the scope of the current U.S. regulations or not, from the very beginning of the use of blockchain technology for the purposes of issuance and trading “tokens of value” (commodities, securities, or cryptocurrencies), the token market was destined and designed for use of the global community. Any exchange or broker would inevitably face the challenge of trading in multiple jurisdictions and dealing with issuers/investors from all over the world.

Additionally, the nature of tokens determines a significant distinction of the blockchain market from a traditional securities market: an issuer needs to create a blockchain platform or use an existing one to issue tokens. As a result, the terms “future tokens” and “simple agreement for future tokens” (SAFT) may very well be treated as distinct securities instruments of the new era: different from options or futures, these tokens represent variations of the unique investment model. Unlike the situation of traditional investment tools, blockchain investors frequently do not receive their tokens instantaneously, rather, the post-investment waiting may take years. Furthermore, an issuance of tokens usually involves the use of ancillary instruments such as cryptographic wallets associated with tokens or other devices that issuers utilize to create and control future marketplace for their security tokens.

As a result, the “future securities tokens” market has developed and actively exists, where initial subscribers are willing to assign their rights to such tokens earlier than tokens are actually issued and become tradable. Whether issuers oppose such practices or not, various agreements and tactics designed to avoid formal non-transferability of future tokens are utilized to arrange the transfer, and profits apparently justify business risks. Said market, since the securities are not registered, is not public. It, nevertheless, exists in the form of communities or clubs, and legal entities that function as “blockchain advisers,” intermediaries, and agents between the potential sellers and potential purchasers of issued or future tokens. The SEC, in its staff statement, drew attention to this matter stating that “an entity that buys, sells, or otherwise transacts or is involved in effecting transactions in digital asset securities for customers or its own account is subject to the federal securities laws, and may be required [my emphasis] to register with the [… SEC and] FINRA.” At this point, the question exists as to how such activity will be interpreted by the SEC, if and when it becomes subject to its review, especially with regard to U.S. entities.

Broker-Dealers. Factors indicating that certain activity may require registration.

Section 15(a)(1) of the Securities Exchange Act of 1934 (the “Exchange Act”) provides that it is unlawful for any broker or dealer to make use of the mails or means or instrumentalities of interstate commerce to effect transactions in any security, or to induce or attempt to induce the purchase or sale of any security [my emphasis], unless that broker or dealer is registered pursuant to the Exchange Act. See 15 U.S.C.A. § 78o (West).[2]

The Exchange Act defines “broker” as “any person engaged in the business of effecting transactions in securities for the account of others.” 15 U.S.C.A. § 78c (West). The term “dealer” is defined to mean “any person engaged in the business of buying and selling securities for his own account,” provided that a person is not in the category “insofar as he buys or sells securities… not as a part of a regular business.[3]” In case law and administrative actions, however, the analysis is usually conducted in a such a manner that a broker and a dealer or a “broker-dealer” is discussed as one category without further classification regarding which definition has been satisfied by the person’s activities.

The list of the activities that may be interpreted as constituting an obligation to register as a broker-dealer can be found on the SEC website and is broad. It includes such examples as finding investors or customers for, making referrals to, or splitting commissions with registered broker-dealers, investment companies (or mutual funds, including hedge funds) or other securities intermediaries, finding investors for “issuers” (entities issuing securities), even in a “consultant” capacity; engaging in, or finding investors for, venture capital or “angel” financings, including private placements; persons that operate or control electronic or other platforms to trade securities; persons that market real-estate investment interests, such as tenancy-in-common interests, that are securities; persons that act as “placement agents” for private placements of securities etc. The factors may be weighted differently, but a commission proportionate to the sale of securities is traditionally considered as one of the strong indicators that tilts the balancing test in favor of the conclusion that the activity is likely to require broker-dealer registration.

Essentially, every issue should be evaluated on an ad hoc basis. In determining whether a particular person falls within the definition of broker-dealer, both the SEC and the courts review the circumstances of the matter from a perspective whether such person is participating in securities transactions “at key points in the chain of distribution.” S.E.C. v. Martino, 255 F. Supp. 2d 268, 283 (S.D.N.Y. 2003) quoting SEC v. Hansen, No. 83 Civ. 3692, 1984 WL 2413, at *10 (S.D.N.Y. Apr. 6, 1984). Although sales-based compensation could be considered as the main “badge” or factor of broker-dealer activity, the “key point” test is extremely flexible and allows to deem an individual or a legal entity as a broker-dealer irrespective to the novelty of the instruments of solicitation or type of securities.

Undoubtedly, certain conclusions can be made based on the existing examples in the SEC’s no-action letters. For instance, the distinction of a broker-dealer from a trader, from the SEC’s point of view, is, inter alia, in the regularity of the subject activity. When a person generally inquires “whether it would be permissible under the federal securities laws… to advertise in an effort to purchase or sell securities for your own account, thereby avoiding use of a broker,” the answer is whether the described activity is engaged in “on a single, isolated basis,” when the registration as broker-dealer is not required, or “is engaged in more often than on a single isolated basis, and if the advertisements encompass offers to buy as well as to sell, broker-dealer registration would be required. Joseph Mcculley Sales, Fed. Sec. L. Rep. P 78,982 (Sept. 1, 1972). Further, there is one peculiar case that may be relevant to the international market of blockchain-based transactions. There, an individual purchasing securities registered with the SEC solely with a registered broker-dealer and further selling them to foreign persons (in Israel) did not require registration as a broker-dealer (although, without an analysis from the SEC whether the factor that the individual intended from a single registered broker-dealer only was relevant). Samuel M. Krieger, 1982 WL 29327, at *1 (July 12, 1982).

It should be additionally noted that the SEC staff has taken and maintained the position that a person who is engaged in the purchase or sale of securities is either a broker-dealer or an associated person. National Ass’n of Sec. Dealers, Inc., SEC No-Action Letter, 1989 WL 246098, Fed. Sec. L. Rep. (CCH) 77,303 (June 18, 1982). “[A] person cannot lawfully engage in the securities business unless he or she is either registered with… [FINRA] as a broker-dealer or as a person associated with a broker-dealer.” Hollinger v. Titan Capital Corp., 914 F.2d 1564, 1573 (9th Cir. 1990).

The implication of the broker-dealer registration requirement on blockchain traders and advisers.

First of all, it is extremely likely that blockchain “advisers,” “experts,” and traders should, at least, consider evaluating their activities as to whether they might be required to register as a broker-dealer. For instance, if a person or an entity can be considered as a “key point” of a token distribution chain, they may face the necessity to register as a broker-dealer.

Secondly, having completed the aforementioned “first step,” an individual or entity may attempt not to subject itself to the U.S. jurisdiction in order to obviate the registration requirements. A lot of unregistered individuals or entities make a decision to “abandon” the United States and function as an offshore entity. Counterintuitively, however, this approach is far from being safe. At the outset, dealing with the U.S. investors by means of interstate commerce automatically subjects persons to the Exchange Act even though a legal entity may be registered abroad: there is no exception for foreign broker-dealers. Further, even exclusion of United States customers from its operations does not automatically release the business having an office in the territory of the United States from the SEC’s jurisdiction. The anti-fraud and consumer protection provisions will still be applicable, and even the registration requirement obligations remain uncertain.

Historically, a registration was not required of broker-dealers when their activities did not involve selling securities to American citizens or residents (See § 1:34. Generally, 15 Broker-Dealer Reg. § 1:34). In fact, the SEC itself in Barons Mortg. Co. of Am. and Intl. Monetary Services, Inc., 1986 WL 67709, at *1 (Aug. 1, 1986) agreed that where securities “will be sold exclusively in foreign countries to non-U.S. residents and non-U.S. citizens” i.e. activities are not involving the US investors, the broker-dealer registration was not necessary. Since then the situation has drastically changed. The Registration Requirements for Foreign Broker-Dealers, 54 FR 30013-01 reads as follows:

the Commission uses an entity approach with respect to registered broker-dealers. Under this approach, if a foreign broker-dealer physically operates a branch in the United States, and thus becomes subject to U.S. registration requirements, the registration requirements and the regulatory system governing U.S. broker-dealers would apply to the entire foreign broker-dealer entity.

To put it simply, the SEC may consider a potential activity of BVI company that trades Swiss-originated securities tokens between China and Singapore, if the BVI company decided that New York is a nice place for its headquarters.

The aforementioned position seems too austere, but it is not likely that an inveterate approach will be easily changed. There is some good news: at least in one instance, solely with regard to the duty to register as a broker-dealer[4] the court found that foreign broker’s failure to be registered in the U.S. was found not actionable when no U.S. investors were involved: “a broker’s failure to register under Section 15(a) of the Act is not actionable in those cases where the ultimate and intended purchase and sale was foreign and thus, itself, outside the scope of the Act.” U.S. S.E.C. v. Benger, 934 F. Supp. 2d 1008, 1013 (N.D. Ill. 2013). Such approach, essentially negating the effect of the SEC’s release addressing foreign-broker dealers was also supported by the Quantum Capital court that straightforwardly called the position “unpersuasive” and agreed with the S.E.C. v. Bengerdecision. See Quantum Capital, LLC v. Banco de los Trabajadores, 1:14-CV-23193-UU, 2015 WL 12259226, at *12 (S.D. Fla. Dec. 22, 2015). The decision as to whether to rely on said case or to stand irresolute seems to be far from obvious. 

Based on the aforesaid, blockchain-oriented businesses should take necessary due diligence steps to make sure that their activities are consistent with the U.S. broker-dealer regulations. Moreover, such notion is relevant not just to the U.S. based entities, but also to registered foreign brokers and international companies with offices in the U.S. It is unclear as to whether the courts will choose the approach of limiting the SEC’s jurisdiction over registration requirements of individuals and legal entities facilitating transactions solely outside of the U.S., as described in S.E.C. v. Benger, or extend the territorial approach beyond the antifraud provisions of the Exchange Act. This uncertainty may raise certain concerns that the U.S. will fall behind other countries in attracting blockchain-related businesses, especially if the allegations about “stonewalling[5]” the broker-dealer applications from companies dealing in crypto assets are justified. It seems, nevertheless, that ultimately, the broker-dealer registration issue is unavoidable and should be preventively addressed by market participates either through a no-action letter or through litigating their own law.

 Kirill Y. Nikonov, Esq. is an attorney at Carmel, Milazzo & Feil LLP

Disclaimer: This article is available for educational purposes only as well as to give readers’ general information and a general understanding of the relevant securities laws, not to provide legal advice of any kind.

[1] Howey test’s prongs were subject to interpretation by numerous court’s decisions, therefore, the reader is respectfully noted that it’s in no event a standalone test. For instance, “investment of money” is also an investment of digital currency (e.g., BTC) or tokens used as money, as interpreted by courts. See Sec. & Exch. Comm’n v. Shavers, No. 4:13-CV-416, 2013 WL 4028182, at *2 (E.D. Tex. Aug. 6, 2013), adhered to on reconsideration, No. 4:13-CV-416, 2014 WL 12622292 (E.D. Tex. Aug. 26, 2014)

[2] The Exchange Act additionally reads: transactions that are exclusively in exempted securities, commercial paper, bankers’ acceptances, or commercial bills do not trigger the registration requirements. This, however, is not applicable to blockchain truncations at this point.

[3] Certain specified exempt activities, such as activities of banks, are not discussed here as irrelevant for the instant article.

[4] An exterritorial approach of the antifraud provisions of Exchange Act are well-established: “in extraterritorial reach of the antifraud provisions… it is clear that Congress “affirmatively and unmistakably” directed that those provisions apply extraterritorially.” Securities and Exch. Commn. v. Scoville, 913 F.3d 1204, 1215 (10th Cir. 2019) Moreover, this aspect of extraterritorial application serves an obvious purpose: avoiding of situations where the masterminds of Ponzi schemes avoid liability by implementing them from the US territory.

[5] https://www.coindesk.com/stonewalled-by-finra-up-to-40-crypto-securities-wait-in-limbo-for-launch


Report this

Published by

CMF represents WallachBeth Capital in the IPO of Guardion Health Sciences Inc. on to the Nasdaq

NEW YORK, NEW YORK, April 5, 2019 – Carmel, Milazzo & DiChiara LLP represents WallachBeth Capital as underwriter for the IPO of Guardion Health Sciences Inc. (“Guardion”) (Nasdaq: GHSI)

Guardion Health Sciences Inc. (“Guardion”) (Nasdaq:GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols.

Continue reading